Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:37 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid Clear all
Withdrawn Phase 2Phase 3 Interventional

Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

NCT02803073
View directory record Official record
Conditions
Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase
Interventions
Testosterone, Normal Saline
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Nov 1, 2026, 4:37 PM EST
Active, not recruiting Phase 2 Interventional Results available

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Fountain Valley, California • Fairfax, Virginia • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 3 Interventional Results available

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

NCT00576251
View directory record Official record
Conditions
Ocular Inflammation Associated With Blepharaconjunctivitis
Interventions
Tobramycin 0.3%/Dexamethasone 0.05%, TOBRADEX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 3 Interventional Results available

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

NCT00352846
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Lymphoma
Interventions
Zoledronic Acid, Vitamin D, Calcium Carbonate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Nov 1, 2026, 4:37 PM EST
Recruiting Phase 2 Interventional

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

NCT04991103
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Nov 1, 2026, 4:37 PM EST
Recruiting Phase 3 Interventional

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Vitamin D, Calcium
Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 1, 2026, 4:37 PM EST
Recruiting Phase 1Phase 2 Interventional

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 1, 2026, 4:37 PM EST
Completed Not applicable Interventional Results available

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

NCT01385280
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Nov 1, 2026, 4:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Potential Vitamin D Effects on Muscle: a Pilot Study

NCT00593996
View directory record Official record
Conditions
Dysphagia, Fecal Incontinence, Urinary Incontinence
Interventions
Ergocalciferol (vitamin D2)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 1, 2026, 4:37 PM EST
Not listed Phase 2 Interventional

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT03942224
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Ixazomib
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02441686
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 4 Interventional

Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children

NCT02298205
View directory record Official record
Conditions
Asthma
Interventions
Asthma controller medication (Beclomethasone) adjustment strategy, Provider-based adjustment
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 3 Interventional Results available

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

NCT00400946
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 1, 2026, 4:37 PM EST
No Longer Available No phase listed Expanded access

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

NCT00826046
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Prochymal®
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
U.S. locations
3
States / cities
Beech Grove, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

NCT02354170
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Roger Goldberg, M.D., MBA
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Walnut Creek, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Nov 1, 2026, 4:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception

NCT00669396
View directory record Official record
Conditions
Pregnancy
Interventions
Copper T380 IUD, levonorgestrel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Nov 1, 2026, 4:37 PM EST
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 1, 2026, 4:37 PM EST
Completed Phase 1 Interventional Results available

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

NCT04848662
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years to 8 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Boerne, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 1, 2026, 4:37 PM EST
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Nov 1, 2026, 4:37 PM EST
Withdrawn Phase 4 Interventional

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

NCT02742805
View directory record Official record
Conditions
Urticaria
Interventions
Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab
Dietary Supplement · Drug
Lead sponsor
Selina Gierer, D.O.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 1, 2026, 4:37 PM EST
Completed Not applicable Interventional Results available

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NCT00350545
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab, Prednisone, Cyclosporine A, tacrolimus
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 1, 2026, 4:37 PM EST